DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stresser, D. M.
Right arrow Articles by Kupfer, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stresser, D. M.
Right arrow Articles by Kupfer, D.

Vol. 27, Issue 4, 517-525, April 1999

Monospecific Antipeptide Antibody to Cytochrome P-450 2B6

David M. Stresser1 and David Kupfer

Department of Pharmacology and Molecular Toxicology, University of Massachusetts Medical Center, Worcester, Massachusetts

To study cytochrome P-450 (CYP) 2B6 contribution to methoxychlor metabolism within human liver microsomes and to initiate an investigation of CYP2B6 protein expression, we developed a polyclonal antibody targeted to a 20-residue peptide within that protein. The antibody was found to be highly sensitive and monospecific for CYP2B6 on immunoblots. Although many immunological studies have described the absence or low expression of CYP2B6 in human livers, in the present investigation, we have found this not to be the case. We immunoquantified CYP2B6 apoprotein expression in a panel of 28 livers and found concentrations ranging from 2 to 82 pmol/mg protein, with a mean value of 25 pmol/mg protein. Five livers (~18%) displayed relatively high levels of CYP2B6 (>40 pmol/mg protein). There were no sex-related differences, although the highest level was observed in a 1-week postpartum donor given several medications. A marked diminution in variability was found in individuals aged 56 or older (n = 12), but there were no age-related trends in mean CYP2B6 content. We suggest that CYP2B6 represents a significant portion of total CYP in human liver. The exquisite sensitivity of this antibody (fmol quantities are detected easily on immunoblots) may explain our detection of CYP2B6 in 100% of livers versus its detection in a limited number of livers by certain other investigators. The antibody also was found to immunoinhibit CYP2B6-catalyzed N-demethylation of (S)-mephenytoin in human liver microsomes by 68 to 79%. The utility of this antibody for determining human liver microsomal CYP2B6 contribution to the ortho-hydroxylation of methoxychlor was demonstrated.

1   Current address: Gentest Corporation, 6 Henshaw Street, Woburn, MA 01801.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 The OncologistHome page
M. Tascilar, W. J. Loos, C. Seynaeve, J. Verweij, and S. Sleijfer
The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas
Oncologist, November 1, 2007; 12(11): 1351 - 1360.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. J. O'Donnell, K. Grime, P. Courtney, D. Slee, and R. J. Riley
The Development of a Cocktail CYP2B6, CYP2C8, and CYP3A5 Inhibition Assay and a Preliminary Assessment of Utility in a Drug Discovery Setting
Drug Metab. Dispos., March 1, 2007; 35(3): 381 - 385.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
B. J. Davies, J. K. Coller, A. A. Somogyi, R. W. Milne, and B. C. Sallustio
CYP2B6, CYP2D6, and CYP3A4 Catalyze the Primary Oxidative Metabolism of Perhexiline Enantiomers by Human Liver Microsomes
Drug Metab. Dispos., January 1, 2007; 35(1): 128 - 138.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. L. Walsky, A. V. Astuccio, and R. S. Obach
Evaluation of 227 Drugs for In Vitro Inhibition of Cytochrome P450 2B6.
J. Clin. Pharmacol., December 1, 2006; 46(12): 1426 - 1438.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. L. Polsky-Fisher, H. Cao, P. Lu, and C. R. Gibson
EFFECT OF CYTOCHROMES P450 CHEMICAL INHIBITORS AND MONOCLONAL ANTIBODIES ON HUMAN LIVER MICROSOMAL ESTERASE ACTIVITY
Drug Metab. Dispos., August 1, 2006; 34(8): 1361 - 1366.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H.-K. Lee, J.-K. Moon, C.-H. Chang, H. Choi, H.-W. Park, B.-S. Park, H.-S. Lee, E.-C. Hwang, Y.-D. Lee, K.-H. Liu, et al.
STEREOSELECTIVE METABOLISM OF ENDOSULFAN BY HUMAN LIVER MICROSOMES AND HUMAN CYTOCHROME P450 ISOFORMS
Drug Metab. Dispos., July 1, 2006; 34(7): 1090 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. L. F. Rehmel, J. A. Eckstein, N. A. Farid, J. B. Heim, S. C. Kasper, A. Kurihara, S. A. Wrighton, and B. J. Ring
INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450
Drug Metab. Dispos., April 1, 2006; 34(4): 600 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. M. Jacob, E. C. Johnstone, M. J. Neville, and R. T. Walton
Identification of CYP2B6 Sequence Variants by Use of Multiplex PCR with Allele-Specific Genotyping
Clin. Chem., August 1, 2004; 50(8): 1372 - 1377.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Turpeinen, R. Nieminen, T. Juntunen, P. Taavitsainen, H. Raunio, and O. Pelkonen
SELECTIVE INHIBITION OF CYP2B6-CATALYZED BUPROPION HYDROXYLATION IN HUMAN LIVER MICROSOMES IN VITRO
Drug Metab. Dispos., June 1, 2004; 32(6): 626 - 631.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. R. Faucette, H. Wang, G. A. Hamilton, S. L. Jolley, D. Gilbert, C. Lindley, B. Yan, M. Negishi, and E. L. LeCluyse
REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERS
Drug Metab. Dispos., March 1, 2004; 32(3): 348 - 358.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. A. Ward, J. C. Gorski, D. R. Jones, S. D. Hall, D. A. Flockhart, and Z. Desta
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 287 - 300.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. Wang, S. R. Faucette, D. Gilbert, S. L. Jolley, T. Sueyoshi, M. Negishi, and E. L. LeCluyse
Glucocorticoid Receptor Enhancement of Pregnane X Receptor-Mediated CYP2B6 Regulation in Primary Human Hepatocytes
Drug Metab. Dispos., May 1, 2003; 31(5): 620 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
P. W. Fan, C. Gu, S. A. Marsh, and J. C. Stevens
Mechanism-Based Inactivation of Cytochrome P450 2B6 by a Novel Terminal Acetylene Inhibitor
Drug Metab. Dispos., January 1, 2003; 31(1): 28 - 36.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Spatzenegger, H. Liu, Q. Wang, A. Debarber, D. R. Koop, and J. R. Halpert
Analysis of Differential Substrate Selectivities of CYP2B6 and CYP2E1 by Site-Directed Mutagenesis and Molecular Modeling
J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 477 - 487.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. Yuan, S. Madani, X.-X. Wei, K. Reynolds, and S.-M. Huang
Evaluation of Cytochrome P450 Probe Substrates Commonly Used by the Pharmaceutical Industry to Study in Vitro Drug Interactions
Drug Metab. Dispos., December 1, 2002; 30(12): 1311 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Lindley, G. Hamilton, J. S. McCune, S. Faucette, S. S. Shord, R. L. Hawke, H. Wang, D. Gilbert, S. Jolley, B. Yan, et al.
The Effect of Cyclophosphamide with and without Dexamethasone on Cytochrome P450 3A4 and 2B6 in Human Hepatocytes
Drug Metab. Dispos., July 1, 2002; 30(7): 814 - 822.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Venkatakrishnan, L. L. von Moltke, M. H. Court, J. S. Harmatz, C. L. Crespi, and D. J. Greenblatt
Comparison between Cytochrome P450 (CYP) Content and Relative Activity Approaches to Scaling from cDNA-Expressed CYPs to Human Liver Microsomes: Ratios of Accessory Proteins as Sources of Discrepancies between the Approaches
Drug Metab. Dispos., April 13, 2001; 28(12): 1493 - 1504.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
L. M. Hesse, K. Venkatakrishnan, M. H. Court, L. L. von Moltke, S. X. Duan, R. I. Shader, and D. J. Greenblatt
CYP2B6 Mediates the In Vitro Hydroxylation of Bupropion: Potential Drug Interactions with Other Antidepressants
Drug Metab. Dispos., October 1, 2000; 28(10): 1176 - 1183.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. T. Nguyen, M. Ramanathan, B. Weinstock-Guttman, K. Dole, C. Miller, M. Planter, K. Patrick, C. Brownscheidle, and L. D. Jacobs
Detection of Cytochrome P450 and Other Drug-Metabolizing Enzyme mRNAs in Peripheral Blood Mononuclear Cells Using DNA Arrays
Drug Metab. Dispos., August 1, 2000; 28(8): 987 - 993.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
T. Shimada, F. Tsumura, and H. Yamazaki
Prediction of Human Liver Microsomal Oxidations of 7-Ethoxycoumarin and Chlorzoxazone with Kinetic Parameters of Recombinant Cytochrome P-450 Enzymes
Drug Metab. Dispos., November 1, 1999; 27(11): 1274 - 1280.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.